Braf protein mutation and its significancy within patients with melanoma

Kuchnicka Julia, Kuchnicka Aleksandra, Kosz Katarzyna, Remjasz Klaudia, Zarankiewicz Natalia, Zielińska Martyna, Sapuła Klaudia, Aleksandrowicz Jakub, Siedlecki Wojciech. Braf protein mutation and its significancy within patients with melanoma. Journal of Education, Health and Sport. 2022;12(8):938-944. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2022.12.08.076

https://apcz.umk.pl/JEHS/article/view/JEHS.2022.12.08.076

https://zenodo.org/record/7017217

 

 

 

 

 

The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. 32343.

Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences).

 

Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 21 grudnia 2021 r. Lp. 32343. Posiada Unikatowy Identyfikator Czasopisma: 201159.

Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).

 

© The Authors 2022;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.

(http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

 

Received: 02.08.2022. Revised: 07.08.2022. Accepted: 23.08.2022.

 

 

 

 

 

BRAF PROTEIN MUTATION AND ITS SIGNIFICANCY WITHIN PATIENTS WITH MELANOMA

MUTACJA BIAŁKA BRAF I JEJ ZNACZENIE DLA PACJENTÓW Z CZERNIAKIEM SKÓRY

Julia Kuchnicka

Szpital Specjalistyczny w Brzezinach

https://orcid.org/0000-0003-0409-5695

Aleksandra Kuchnicka

Absolwent Uniwersytetu Medycznego w Lublinie

https://orcid.org/0000-0001-8481-7592

Katarzyna Kosz

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

https://orcid.org/0000-0001-6848-0598

Klaudia Remjasz

Absolwent Warszawskiego Uniwersytetu Medycznego

https://orcid.org/0000-0002-0879-7515

Natalia Zarankiewicz

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

https://orcid.org/0000-0001-9203-3376

Martyna Zielińska

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

https://orcid.org/0000-0001-8886-8274

Klaudia Sapuła

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

 https://orcid.org/0000-0003-2436-0150

Jakub Aleksandrowicz

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

https://orcid.org/0000-0002-4534-9682

Wojciech Siedlecki

1 Wojskowy Szpital Kliniczny w Lublinie

https://orcid.org/0000-0002-9917-5411

 

 

 

Abstract

Introduction and purpose:

This review aims to analyze BRAF mutation significancy and its influence on progression and therapy methods within patients with melanoma.

Material and method:

This review was mainly based on articles collected in Pubmed in years 2004-2018. The research was done by looking through keywords as follows “braf kinase”, “braf mutation”, “melanoma” “wemurafenib”.

Results:

The selected studies have demonstrated that it is justified to identify patient with BRAF mutation due to it’s influence on treatment’s method choosing.

Conclusions:

Citied researches have proven BRAF mutation significancy in growth and progressions of many malignant tumors. Further tests are likely to not only prolong life expectancy within patients with melanoma, but also being a source of crucial knowledge about tumors development.

 

Keywords :braf kinase, braf mutation, melanoma, wemurafenib